Artificial lung developer ALung raises $12m
Artificial lung-like device developer ALung Technologies said today it closed a $12 million round of financing to support the continued commercialization of its minimally invasive Hemolung Respiratory Assist System. Pittsburgh-based ALung’s Hemolung device is an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein. “This new financing reflects continued recognition by the investment community of the potential for our Hemolung technology to revolutionize the treatment of patients with acute respiratory failure. Very importantly, we will utilize this financing to complete the work required to obtain IDE approval for a US-based clinical trial under our recent EAP designation. We are very grateful to our investors for their continued confidence as we pursue this very exciting next step,” CEO Peter DeComo said in a prepared statement. ALung said the funds came from existing and new investors, and in addition to commercialization, funds will help support the company’s pursuit of FDA approval following the agency’s Expedited Access Pathway designation. The company raised $10.8 million of the funds last month, according to an SEC filing it posted in mid-January. The money already raised in the round comes from 63 unnamed investors, according to the SEC filing. The company said that the remaining ...
In conclusion, salidroside inhibited the survival, migration and invasion of NSCLC cells. Salidroside blocked AKT and the MEK/ERK signal pathway by upregulating miR-195 expression in A549 cells. PMID: 30880481 [PubMed - in process]
I read with great interest the original article by Oishi and colleagues1 and the corresponding letter to the Editor composed by Katz and colleagues. Oishi and colleagues' work is one of the most recent publications from the Toronto lung transplant laboratories and has to be interpreted as such. Having established a protocol, which can be used to safely perfuse human donor lungs ex vivo, the research group has consequently taken the next step and applies this platform to treat and improve organs.
Natalie Jarvis has been inundated with offers of help since speaking out last week about the significant financial costs faced by Atlantic Canadian patients who must move to Toronto for lung transplants, and now she's asking people to help others in similar situations.
Volume 47, Issue 1, December 2019, Page 1014-1021 .
AbstractIntroductionThere is a strong association between cystic fibrosis and malnutrition, mainly because of the higher energy needs combined with lower intake. There is also a well-established correlation between good nutritional status and better lung function. To date, however, there are no studies examining nutritional status in childhood and adult lung function. To respond to this need, this innovative study explored the long-term correlations between nutritional status in childhood and lung function in adulthood for the same patient population.MethodsA retrospective patient file study was conducted to identify putat...
PMID: 30884244 [PubMed - as supplied by publisher]
Frailty is common in adults with end-stage lung disease and is associated with death before and after lung transplantation. We aimed to determine whether frailty changes from before to after lung transplant.
END-STAGE HEART FAILURE (HF) results from a myriad of etiologies and represents a major financial and healthcare burden.1 Since 1983, nearly 150,000 pediatric and adult heart transplants have been reported to the International Society for Heart and Lung Transplantation (ISHLT) Registry, with medical advancements in perioperative care resulting in improved patient outcomes over time.2 This paper aims to assess outcomes within the field of heart transplantation. The authors will focus on historical context, current demographics, indications, and contraindications for transplantation.
Right-sided heart failure develops in lung transplantation candidates on prolonged peripheral extracorporeal membrane oxygenation support and is a major determinant of mortality. The use of central venoarterial extracorporeal membrane oxygenation for bridging of right-sided heart failure to lung transplantation was evaluated.
This study provides a possible reason why genes carrying health risks have persisted in human populations. The second found evidence for multiple variants in genes related to ageing that exhibited antagonistic pleiotropic effects. They found higher risk allele frequencies with large effect sizes for late-onset diseases (relative to early-onset diseases) and an excess of variants with antagonistic effects expressed through early and late life diseases. There also exists other recent tangible evidence of antagonistic pleiotropy in specific human genes. The SPATA31 gene has been found under strong positive genomic sele...